|
Schirdewan博士的引述的參考文獻:
?2 Y7 X0 j& R4 m5 N' Y3 }( C
6 f. c7 ^% Z; }Camm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009.
5 o( a) G4 z4 K' t H' D' q7 _3 t+ D
6 D& A. x, v, O+ R' B7 o/ EDaubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008 $ V; a. \/ i6 J) @# v( H
% ~; g" Z( B; x _1 V# m6 J
Ricci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010.
( o* d7 u* p( x- ~2 \: }2 A% \- s! ]( D
關於BIOTRONIK SE & Co. KG
$ G5 }4 a4 g8 n4 B/ z
" F- z0 F' [$ }+ P, v/ d, cBIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|